Moderna's experimental flu vaccine — built on the same messenger RNA technology that reshaped the COVID-19 pandemic response — has cleared a major regulatory milestone. On June 18, 2026, the FDA's top vaccine advisory committee voted 9-0 to recommend the vaccine, called mFlusiva, for adults aged 50 and older.
The unanimous vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) sets the stage for what would be the first mRNA-based seasonal influenza vaccine ever approved in the United States. The FDA's final decision is expected by August 5, 2026 — potentially in time to make the vaccine available this coming fall.
